Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Multicentric Castleman Disease


Other Names for this Disease
  • Idiopathic multicentric Castleman's disease
  • MCD
  • Multicentric angiofollicular ganglionic hyperplasia
  • Multicentric angiofollicular lymph hyperplasia
  • Multicentric Castleman's disease
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might multicentric Castleman disease be treated?

The treatment of multicentric Castleman disease (MCD) varies based on the severity of the condition and whether or not the patient has an HIV and/or human herpes virus type 8 (HHV-8) infection. Possible treatment options include:[1][2][3]
  • Immunotherapy can be used to block the action of the interleukin-6 (IL-6), a protein that is produced in excess by the immune system of people with MCD
  • Chemotherapy may be recommended to slow the growth of lymphatic cells
  • Corticosteroid medications can reduce inflammation
  • Anti-viral drugs can block the activity of HHV-8 or HIV (in people who are infected by these viruses)
Last updated: 6/25/2015

References
  1. Castleman Disease. American Cancer Society. July 2014; http://www.cancer.org/cancer/castlemandisease/detailedguide/index.
  2. Neetu Radhakrishnan, MD. Castleman Disease. Medscape Reference. January 2015; http://emedicine.medscape.com/article/2219018-overview.
  3. Jon C Aster, MD; Jennifer R Brown, MD, PhD; Nikhil C Munshi, MD. Multicentric Castleman's disease. UpToDate. January 2015; Accessed 6/25/2015.


GARD Video Tutorial

  • Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.

    Finding Treatment Information

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Multicentric Castleman Disease. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
  • The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research. Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the "Text Search" box. Then click "Submit Query".

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name siltuximab
Trade Name
(Manufacturer Name)
Sylvant
(Janssen Biotech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Idiopathic multicentric Castleman's disease
  • MCD
  • Multicentric angiofollicular ganglionic hyperplasia
  • Multicentric angiofollicular lymph hyperplasia
  • Multicentric Castleman's disease
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.